Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of the Dopaminergic and Glutamatergic Systems, and a Serotonin Reuptake Inhibitor - ResearchAndMarkets.com
May. 16, 2018
DUBLIN--(BUSINESS WIRE)--May 16, 2018--The "Drug Overview: lumateperone" report has been added to ResearchAndMarkets.com's offering.
Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulator of the dopaminergic and glutamatergic systems, and a serotonin reuptake inhibitor. By targeting the serotonergic and dopaminergic systems, the drug appears to reduce agitation and minimize positive symptoms. Its additional actions on glutamatergic signaling are believed to help address both negative and cognitive schizophrenia symptoms.
Intra-Cellular Therapies licensed lumateperone from its original developer, Bristol-Myers Squibb, in 2005, and is now solely responsible for the drug's development. In December 2015, the company announced the initiation of patient enrollment for its two Phase III trials in bipolar depression. Additional clinical programs with lumateperone include its Phase III development in schizophrenia and behavioral disturbances in dementia.
Key Topics CoveredDrug Overview Product Profiles lumateperone: Bipolar Disorder lumateperone: Schizophrenia
List of Figures
Figure 1: Lumateperone for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for lumateperone in bipolar disorder
Figure 3: Drug assessment summary for lumateperone in bipolar disorder
Figure 4: Lumateperone for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of lumateperone for schizophrenia
Figure 6: Drug assessment summary of lumateperone for schizophrenia
Figure 7: Lumateperone sales for schizophrenia in the US, 2017-26
List of Tables
Table 1: Lumateperone drug profile
Table 2: Lumateperone Phase III trials in bipolar disorder
Table 3: Lumateperone drug profile
Table 4: Lumateperone Phase II and Phase III data in schizophrenia
Table 5: Lumateperone other interim Phase II data in schizophrenia
Table 6: Lumateperone sales for schizophrenia in the US ($m), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/fdlpbx/lumateperone?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005524/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 05/16/2018 05:00 AM/DISC: 05/16/2018 05:00 AM